Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v7-EN | Version v1-EN | |
|---|---|---|
| Language | English | English |
| Date Updated | 2023-03-14 | 2022-12-28 |
| Drug Identification Number | 00009881 | 00009881 |
| Brand name | PAPAVERINE HYDROCHLORIDE INJECTION USP | PAPAVERINE HYDROCHLORIDE INJECTION USP |
| Common or Proper name | PAPAVERINE HYDROCHLORIDE | PAPAVERINE HYDROCHLORIDE |
| Company Name | SANDOZ CANADA INCORPORATED | SANDOZ CANADA INCORPORATED |
| Ingredients | PAPAVERINE HYDROCHLORIDE | PAPAVERINE HYDROCHLORIDE |
| Strength(s) | 65MG | 65MG |
| Dosage form(s) | LIQUID | LIQUID |
| Route of administration | SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR | SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR |
| Packaging size | 2ML | 2ML |
| ATC code | A03AD | A03AD |
| ATC description | DRUGS FOR FUNCTIONAL BOWEL DISORDERS | DRUGS FOR FUNCTIONAL BOWEL DISORDERS |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | ||
| Actual start date | 2022-12-21 | 2022-12-21 |
| Estimated end date | 2023-03-10 | 2023-01-20 |
| Actual end date | 2023-03-13 | |
| Shortage status | Resolved | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | ||
| Health Canada comments |